Get the Stockscreener App
3.1095
2.52%
-0.0805
Jupiter Neurosciences Inc stock is traded at $3.1095, with a volume of 15,845.
It is down -2.52% in the last 24 hours and up +3.31% over the past month.
Jupiter Neurosciences Inc is a clinical-stage research and development company focused on developing treatments for neuroinflammation through the resveratrol platform. Its platform product, JOTROL, is an enhanced oral formulation of resveratrol, which has many potential indications. In the larger disease areas, which are targeting Parkinson's Disease. The group is presently in the process of conducting a Phase IIa clinical trial in Parkinson's Disease. The company operates through two reportable segments: premium nutritional supplements and pharmaceutical operations focused on drug candidates for CNS and rare orphan diseases. It generates the majority of its revenue from Premium Nutritional Supplements, which includes commercialization and sales of the Company's Nugevia product line.
See More
Previous Close:
$3.19
Open:
$3.16
24h Volume:
15,845
Relative Volume:
0.13
Market Cap:
$4.10M
Revenue:
$40,400
Net Income/Loss:
$-9.18M
P/E Ratio:
-11.59
EPS:
-0.2684
Net Cash Flow:
$-5.78M
1W Performance:
+12.26%
1M Performance:
+3.31%
6M Performance:
-89.59%
1Y Performance:
-97.27%
1-Day Range:
$3.025
$3.27
1-Week Range:
$2.67
$3.4999
52-Week Range:
$2.251
$135.75
Jupiter Neurosciences Inc Stock (JUNS) Company Profile
Name
Jupiter Neurosciences Inc
Sector
Industry
Phone
(561) 406-6154
Address
1001 NORTH US HWY 1, JUPITER
Compare JUNS vs VRTX, MRNA, REGN, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
JUNS
Jupiter Neurosciences Inc
|
3.1095 | 4.10M | 40,400 | -9.18M | -5.78M | -0.2684 |
VRTX
Vertex Pharmaceuticals Inc
|
508.71 | 128.94B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
238.63 | 95.27B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
799.98 | 82.36B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
855.28 | 53.79B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
374.53 | 42.37B | 5.76B | 514.49M | 1.10B | 4.4813 |
Jupiter Neurosciences Inc Stock (JUNS) Latest News
Its share price met one Nasdaq rule. Jupiter Neurosciences (NASDAQ: JUNS) still faces delisting. - Stock Titan
Certain Stock Options of Jupiter Neurosciences, Inc. are subject to a Lock-Up Agreement Ending on 23-SEP-2026. - marketscreener.com
Certain Common Stock of Jupiter Neurosciences, Inc. are subject to a Lock-Up Agreement Ending on 23-SEP-2026. - marketscreener.com
Jupiter Neurosciences (Nasdaq: JUNS) lowers meeting quorum to one-third - Stock Titan
Jupiter Neurosciences, Inc. Warrants (JUNSW) Peer Comparison – Compare with Others - Value Research
Orca Capital AG Discloses 3.3% Passive Stake in Jupiter Neurosciences (NASDAQ: JUNS) - Kalkine Media
Jupiter Neurosciences (NASDAQ: JUNS) Faces Nasdaq Capital Market Delisting Over $35M Market-Value Deficiency - kalkinemedia.com
Weekly Roundup on the Cannabis Sector & Psychedelic Sector - marketexclusive.com
Jupiter Neurosciences Received Notice of Delisting - tradingview.com
Jupiter Neurosciences (NASDAQ: JUNS) to appeal Nasdaq delisting - Stock Titan
Jupiter Neurosciences Faces Nasdaq Delisting Risk Despite Compliance - TipRanks
Jupiter (JUNS) Quarterly Results: The Available Earnings Metric Delivers a Beat in Latest Trading; Latest Reaction: Shares Move Lower 8.66% for the Current SessionTax Rate Impact - vinanet.vn
Jupiter Neurosciences Gains Relief from Insider Debt Forgiveness - TipRanks
Jupiter Neurosciences (JUNS) starts drawing on $20M equity line after new stock deal - Stock Titan
Jupiter Neurosciences (NASDAQ: JUNS) raises $2M as Nasdaq review continues - Stock Titan
Jupiter Neurosciences Raises $2.0 Million in Registered Direct Offering - minichart.com.sg
Jupiter Neurosciences Prices $2.0 Million Registered Direct Offering at $6.50 Per Share - TradingView
Jupiter Neurosciences Stock Surges Friday: What's Driving the Action? - Sahm
JUNS Jumps As Jupiter Neurosciences Prices Equity Deal - StocksToTrade
Jupiter Neurosciences, Inc. stock plunges 44% after spiking to $11.14 - Cryptonews.net
Jupiter Neurosciences, Inc. stock Analysis: August 2026 Volatility & Trend Review - The Cryptonomist
Best Pharmaceutical Stocks To Watch TodayAugust 21st - MarketBeat
Friday's session: most active stocks - ChartMill
12 Health Care Stocks Moving In Friday's Intraday Session - Benzinga
Jupiter Neurosciences Prices $2.0 Million Direct Offering - marketscreener.com
Jupiter Neurosciences Announces Pricing of $2.0 Million Registered Direct Offering - The Manila Times
Jupiter Neurosciences Announces Pricing of $2.0 Million Registered Direct Offering - GlobeNewswire
Jupiter Neurosciences Jumps 59% as Volume Hits 59 Times Its Share Count - TechStock²
Jupiter Neurosciences Surges as Post-Split Float Shrinks and Traders Revisit Pipeline Expansion - quiverquant.com
JUNS Stock Whipsaws As New Insider Ownership Is Disclosed - timothysykes.com
JUNS Stock Draws Focus After New Insider Ownership Filing - StocksToTrade
Jupiter Neurosciences Stock Surges Friday: What's Driving the Action? - Benzinga
JUNS Stock Jumps As New Insider Ownership Revealed - StocksToTrade
JUNS Stock Jumps As New Insider Ownership Comes To Light - timothysykes.com
Which stocks are moving before the opening bell on Friday? - ChartMill
12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga
JUNS Stock Whipsaws As New Insider Files Form 3 - StocksToTrade
Jupiter Neurosciences Announces Pricing of $2.0 Million Registered Direct Offering - Yahoo Finance
Jupiter Neurosciences proposes selling 307,692 shares for about $2 million - Stock Titan
Jupiter (JUNS) Trading: Posts a 3.81% Loss to $4.80 on the Day; Immediate View: the $4.56 to $5.04 Range Remains in Focus in the Current UpdateEase of Movement - vinanet.vn
Andrew Jon Cutler Net Worth (2026) - GuruFocus
Real Parkinson’s Disease Hope from Jupiter Neurosciences - Yahoo Finance
Jupiter Neurosciences, Inc. announced that it has received $0.774787 million in funding - marketscreener.com
Jupiter (JUNS) Quarterly Figures: EPS Lands Above Forecast in the Latest Session; Post-Report Move: Shares Finish 3.67% Down in the Current UpdateDebt Analysis Report - Vinanet
Jupiter Neurosciences, Inc. Common Stock (NASDAQ: JUNS) Stock Price, News & Analysis - Kalkine
JUNS Q4 2025 Earnings: Narrower-Than-Expected Loss Meets 6.16% Surprise but Shares Slide 12.67%Dividend Earnings Report - vinanet.vn
JUNS Q4 2025 Earnings: Narrower Loss Beats Estimates; Shares Slide 12.67%EPS Surprise History - vinanet.vn
JUNS Q4 2025 Earnings: Smaller Loss per Share Beats Estimate, But Shares Slip 12.67%Earnings Call Highlights - vinanet.vn
Jupiter Neurosciences, Inc. Common Stock (NASDAQ: JUNS) Stock Price, News & Analysis - kalkine.ca
Jupiter Neurosciences Inc (JUNS) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Jupiter Neurosciences Inc Stock (JUNS) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.42%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):